由刘勇军、董晨、苏冰、邵峰领衔策划的BIOCHINA2024(EBC)科学家峰会，旨在邀请全球和中国有影响力、有科研创新能力的科学家出席，向中国生物医药行业传递科研创新力量，同时也希望向全球传播中国生物医药行业产业优势。同期也将开设BIOCHINA2024(EBC)青年科学家峰会，期待更多行业年轻力量得以彰显。
时间：2024年3月15日
地点：苏州国际博览中心
主席：刘勇军、董晨、苏冰、邵峰
10:00-10:45
致辞&报告
刘勇军，信达生物总裁、吉林大学唐敖庆客座教授
10:45-10:50
Q&A
10:50-11:30
报告: Metabolic and Neural Regulation of Immunity and Cancer
Tak W. Mak, Director,CampbellFamily Institute for BreastCancer Research,
Princess Margaret Cancer Centre, University of Toronto
11:30-11:35
Q&A
11:35-12:15
报告
董晨，中国科学院院士、上海市免疫治疗创新研究院院长
12:15-12:20
Q&A
13:15-14:30
圆桌讨论
刘勇军，信达生物总裁、吉林大学唐敖庆客座教授
董晨，中国科学院院士、上海市免疫治疗创新研究院院长
邵峰，中国科学院院士、北京生命科学研究所副所长、清华大学讲席教授、炎明生物科学创始人
苏冰，上海交通大学王宽诚讲席教授、上海市免疫学研究所所长
Tak W.Mak, Director, Campbell Family Institute for Breast Cancer Research, Princess Margaret Cancer Centre, University of Toronto
Eicke Latz, Scientific Director, Deutsches Rheuma Forschungszentrum Berlin
Michael Karin, Distinguished Professor of Pharmacology, University of California,San Diego(UCSD)
14:30-15:10
报告:NLRP3 inflammasome biology - from bench to bedside
Eicke Latz, Scientific Director, Deutsches Rheuma Forschungszentrum Berlin
15:10-15:15
Q&A
15:15-15:55
报告
邵峰，中国科学院院士、北京生命科学研究所副所长、清华大学讲席教授、炎明生物科学创始人
15:55-16:00
Q&A
16:00-16:40
报告
苏冰，上海交通大学王宽诚讲席教授、上海市免疫学研究所所长
16:40-16:45
Q&A
16:45-17:25
报告: A Novel Metabolic Checkpoint That Controls Progression From Hepatocyte Senescence to Cancer Michael Karin, Distinguished Professor of Pharmacology, University of California,San Diego(UCSD)
17:25-17:30
Q&A
嘉宾介绍
嘉宾简介：
信达生物制药集团总裁，吉林大学唐敖庆讲席教授，华普生物制药科学创始人，在国际著名科研机构和全球顶尖制药企业研发部门拥有丰富的工作经历。
刘博士于1984年于白求恩医科大学取得内科医学学位，1989年于英国伯明翰大学医学院获得免疫学博士学位，并于两年后在该校完成博士后项目培训。1991年加入跨国制药公司法国里昂先灵葆雅，1997年加入先灵葆雅旗下美国生物技术公司 DNAX 研究所担任主任科学家。2002年，被美国德克萨斯大学安德森癌症中心聘为杰出讲席教授、免疫学系主任和癌症免疫研究中心创始主任。2011年，被贝勒研究所聘为首席科学官和贝勒免疫研究所所长。2014年被阿斯利康旗下全球生物制药子公司 Medimmune 聘为首席科学官和全球研究负责人。2016年至2020年期间担任赛诺菲全球研究负责人。
刘博士拥有丰富的科研成果和科研机构经历，他在 Nature 和 Science 等顶尖学术期刊上共发表了超过260篇论文，总引用次数超过10万次。推动了多个领域的临床前研究，使得许多候选药物从最初的实验室发现走向临床，惠及病患。
嘉宾简介：
董晨教授是中国科学院院士，现任上海交通大学校长助理、上海市免疫治疗创新研究院院长、上海交通大学医学院和药学院讲席教授， 首届新基石研究员，他还是清华大学医学院教授（双聘）、清华大学免疫学研究所PI。董晨1989年本科毕业于武汉大学，1996年获美国阿拉巴马大学伯明翰分校博士学位， 1997至2000年在美国耶鲁大学免疫学系从事博士后工作。曾任美国得克萨斯大学MD Anderson 癌症中心免疫学系终身讲席教授、炎症与肿瘤中心主任。2013年回国工作后，曾任清华大学免疫学研究所所长，清华大学医学院院长。
董晨院长主要致力于免疫学的研究，在T细胞分化和自身免疫疾病领域做出了多项开创性贡献，其研究对于治疗免疫性疾病带来了深远的影响, 也给肿瘤免疫治疗提供新的思路，其中定义Th17和Tfh细胞的工作，2021年被Nature Reviews Immunology评为免疫学过去20年最重要的20项突破中的两项, 也在2022年被Nature Milestones列入T细胞领域历史上的20个重大里程碑。董晨院长目前已发表论文280篇，总被引用次数达35000余次，曾七次被评为全球“高被引科学家”。董晨是美国科学促进会会士、中国医学科学院学部委员, 曾获得2009年美国免疫家学会BD Bioscience研究者奖、2019年国际细胞因子与干扰素协会Biolegend-William E. Paul Award奖, 他还被授予吴阶平医药创新奖、吴杨医学奖等。他是基金委”炎症生物学与疾病”创新群体负责人。现任Current Opinion in Immunology和hLife的共同主编、Frontiers in Immunology·T Cell Biology主编, 中国科学·生命科学常务副主编、Advances in Immunology副主编, Annual Review in Immunology、Immunity、Med和Cell Research等期刊的编委或科学顾问。
中国科学院院士
北京生命科学研究所副所长
清华大学讲席教授
炎明生物科学创始人
嘉宾简介：
邵峰博士1996年毕业于北京大学技术物理系，1999年于中科院生物物理所获得硕士学位，2003年于密西根大学生物化学系获得博士学位，现为北京生命科学研究所资深研究员、科研副所长。
邵峰博士在天然免疫和细胞焦亡领域做出重要贡献：鉴定了多个针对细菌的胞内免疫受体，包括识别LPS的caspase-11；进一步发现并阐明了炎症小体和caspase蛋白通过剪切活化Gasdermin D（GSDMD）诱导焦亡的分子机制，为败血症和炎性疾病的药物研发提供了新的靶点，Gasdermin家族膜打孔蛋白的鉴定也重新定义了细胞焦亡，开辟了细胞死亡和免疫研究新方向。邵峰博士还发现caspase-3可以活化GSDME引发细胞焦亡，是化疗药物毒副作用的重要原因；细胞焦亡还是淋巴细胞毒性的关键机制，肿瘤细胞焦亡可诱发强烈的抗肿瘤免疫反应。
邵峰博士已发表学术论文100多篇，以通讯作者在Nature、Science和Cell杂志发表研究论文19篇，总引用40,000多次；获得多个重要奖项，包括未来科学大奖、基础和肿瘤免疫学大奖William B. Coley Award、求是杰出科学家奖、陈嘉庚科学、北京市科学技术最高奖（突出贡献中关村奖）、HHMI国际青年科学家奖、何梁何利科学与技术奖、国际蛋白质学会鄂文西格青年科学家奖、谈家桢生命科学成就奖以及吴阶平-保罗杨森基础医学奖等，并于2015年当选为中科院院士和EMBO的外籍成员，2016年当选为美国微生物学院会士，2019年当选为德国国家科学院院士。
嘉宾简介：
上海交通大学王宽诚讲席教授、上海市免疫学研究所所长，上海交通大学医学院免疫与微生物学系主任、教授，瑞金医院免疫相关疾病研究中心主任和首席科学家，上海交通大学医学院-耶鲁大学免疫代谢研究院主任，国家高层次人才计划专家，上海交通大学致远荣誉博士生导师，国家科技部重点研发计划首席科学家，美国耶鲁大学、上海中医药大学、和中南大学湘雅医院客座教授。1984年获得北京大学理学学士学位，同年考取CUSBEA中美留学项目入学耶鲁大学，1987、1991年分别获美国耶鲁大学硕士、博士学位，1991-1995年在美国加州大学圣地亚哥分校从事博士后工作。1995-2014年分别是美国德州大学MD安德森癌症中心担任终身教授和耶鲁大学担任终身教授。苏冰教授研究主要聚焦于MAPK和mTOR信号通路在肠道间质细胞、巨噬细胞、T、B细胞和固有样淋巴细胞以及血管细胞的调控机制及其在肠道炎症、肿瘤、纤维化、心脑血管等疾病中的生理病理作用。在Nature、Cell、Immunity、Nature Genetics等顶尖学术发表论文150篇,他引超过21000次。苏冰教授主持多项科研项目，包括美国NIH、ACS、DOD、AHA、LLS、Irvington Fellowship以及国家科技部、国家自然科学基金委重大研究计划、重点项目、国际合作项目以及上海市科委、卫计委等项目。此外，苏冰教授曾担任美国华人生物学家协会秘书长和理事会委员，现任《现代免疫学》杂志主编，Journal of Molecular Cell Biology和Current Research in Immunology杂志副主编，《中国科学SCLS》、STTT等杂志编委，是国家自然基金委重点/面上项目、CJ及美国NIH、AHA等多个学科组的专业委员和项目评审专家。
Director，Campbell Family Institute for Breast Cancer Research, Princess Margaret Cancer Centre, University of Toronto
嘉宾简介：
Director, Campbell Family Institute for Breast Cancer Research, Princess Margaret Cancer Centre, University of Toronto, Toronto, Canada
Director, Centre of Oncology and Immunology, InnoHealth, and Department of Pathology, University of Hong Kong
Tak W. Mak is internationally known for his pioneering work on the genetics and molecular biology of cancer and the immune system. His group was the first to clone the gene encoding the human T cell receptor, providing the basis for CAR-T and TCR-T treatments. His team also showed that CTLA4 negatively regulates T cell activation, paving the way for checkpoint inhibitor immunotherapy. Most recently, his team established that the brain communicates with the immune system via T and B cells producing acetylcholine.
In the biotech arena, Dr. Mak was the Vice President of Research at Amgen as well as co-founded several companies including Agios Pharmaceuticals and Treadwell Therapeutics. These companies specialize in developing first-in-class drugs delineating metabolic and immunological vulnerabilities in tumour cells that can be exploited as novel therapies. Two IDH inhibitors and one drug directed at PKR are now FDA-approved for AML treatment and anemia patients, respectively. At Treadwell, three first-in-class agents targeting aneuploidy and immunotherapy focused on advanced cancers are now in phase II clinical trials .
Dr. Mak has published 1000 peer-reviewed research papers, holds dozens of patents, won numerous scientific and medical awards and is a recipient of a dozen Honorary degrees in Europe, Asia and North America.
Scientific Director Deutsches Rheuma Forschungszentrum Berlin
嘉宾简介：
Prof. Dr. (med.) Eicke Latz studied medicine at the Georg-August University in Göttingen and the Freie Universität Berlin, following which, he worked as an intensive care physician at the Charité Universitätsmedizin. In 2001, he moved to the USA, working as a postdoctoral researcher at Boston University, then at UMass Chan Medical School, where he held his first professorship. In 2010, he returned to Germany and founded the Institute for Innate Immunity at the University Hospital Bonn. He became Scientific Director of the German Rheumatism Research Centre Berlin, a Leibniz Institute, and Professor of Experimental Rheumatology at the Charité Universitätsmedizin Berlin in 2023. His research interests concern how the innate immune system maintains health and under what circumstances it can promote disease. In particular, he investigates the molecular mechanisms that lead to activation or inhibition of the immune system and how these influence the inflammatory reactions in various diseases, such as rheumatic diseases, arteriosclerosis or Alzheimer’s disease.
Prof. Dr. Latz is co-spokesperson of the Cluster of Excellence “ImmunoSensation²” and spokesperson of the Collaborative Research Centre “Metaflammation and Cellular Programming” (SFB 1454). He has also co-founded several biotech companies, including IFM Therapeutics (2017), Dioscure Therapeutics (2020), a 'Stealth' biotech' (2020), and Odyssey Therapeutics (2021), which translate his discoveries into novel therapeutics and preventive approaches. He has been a highly cited scientist in immunology since 2014 having published more than 300 publications. Prof. Dr. Latz was elected as a member of the German National Academy of Sciences (Leopoldina) in 2016 and has received a number of prestigious awards, including the Gottfried Wilhelm Leibniz Prize in 2018.
Distinguished Professor of Pharmacology, University of California,San Diego(UCSD)
嘉宾简介：
I have spent my academic career investigating stress and inflammation signaling, covering the entire gamut of experimental approaches from biochemistry and molecular cell biology to animal pathophysiology. Discovering how infection, inflammation, radiation, or environmental stressors activate AP-1, NF-κB and other transcription factors, I studied how these findings apply to the pathogenesis of cancer, degenerative and metabolic diseases.
My group has elucidated fundamental mechanisms through which inflammation and obesity promote tumor development and contribute to type II diabetes and insulin resistance. We were among the first to highlight the role of inflammation in metabolic disease. We established the mechanisms through which members of the IL-6 cytokine family control development of colorectal (CRC) and liver (HCC) cancers through activation of STAT3 and YAP and established the cell type specific mechanisms through which NF-κB activation via IκB kinases(IKK), which we were the first to discover, affect the pathogenesis of various cancers. We discovered that not only innate immune cells, namely macrophages, but also adaptive immune cells, T regulatory cells and Blymphocytes, contribute to tumorigenesis. Through this work, I contributed to establishment of the Inflammation and Cancer field. More recently, we demonstrated the existence of immunosuppressive plasma cells and their role in negative regulation of immunosurveillance and immunotherapy. Our current work is focused on HCC,CRC, and pancreatic ductal adenocarcinoma (PDAC). We established robust and accurate mouse models for studying non-alcoholic steatohepatitis (NASH)-induced HCC and chronic pancreatitis-accelerated PDAC and used them to discover how adaptive immunity controls HCC development and the role of the autophagy substrate p62 in inflammation and HCC and PDAC pathogenesis. We discovered how activation of the p62-KEAP1-NRF2 cascade confers resistance to autophagy inhibitors and established a new PDAC and HCC therapeutic approach targeting autophagy and macropinocytosis. We used our mouse models to study how metabolism and nutrition affect NASH and HCC development focusing on the adverse effects of fructose and alcohol intake and toxicants.
